Familial amyloidotic polyneuropathy (FAP) is a neurodegenerative disorder characterized by extracellular deposition of amyloid fibrils composed by mutated transthyretin (TTR) mainly in the peripheral nervous system. At present, liver transplantation is still the standard treatment to halt the progression of clinical symptoms in FAP, but new therapeutic strategies are emerging, including the use of TTR stabilizers. Here we propose to establish a new gene therapy approach using adeno-associated virus (AAV) vectors to deliver the trans-suppressor TTR T119M variant to the liver of transgenic TTR V30M mice at different ages. This TTR variant is known for its ability to stabilize the tetrameric protein. Analysis of the gastrointestinal tract of AAV-treated animals revealed a significant reduction in deposition of TTR non-fibrillar aggregates in as much as 34% in stomach and 30% in colon, as well as decreased levels of biomarkers associated with TTR deposition, namely the endoplasmic reticulum stress marker BiP and the extracellular matrix protein MMP-9. Moreover, we showed with different studies that our approach leads to an increase in tetrameric and more stable forms of TTR, in favor of destabilized monomers. Altogether our data suggest the possibility to use this gene therapy approach in a prophylactic manner to prevent FAP pathology.
INTRODUCTION
Familial amyloidotic polyneuropathy (FAP) is an autosomal dominant hereditary disease caused by mutations in the transthyretin (TTR) gene, and characterized by the extracellular deposition of TTR amyloid fibrils predominantly in the peripheral nervous system. 1 TTR is mainly synthesized in the liver and choroid plexus epithelium in the brain and is a transport protein of thyroxine (T 4 ) in plasma and cerebrospinal fluid.
2 TTR is found in biological fluids as a homotetrameric protein composed of 127 amino-acid polypeptide subunits. Disease-associated mutations have been shown to reduce the thermodynamic stability of the tetramer, 3 as it is the case of the V30M mutation. Therefore, TTR tetramers containing mutant monomers have a higher propensity to dissociate into compact non-native monomers with low conformational stability that can lead to amyloid fibril formation. 4 Orthotopic liver transplantation has been widely reported to halt the progression of clinical manifestations, when performed at early stage of disease. It is currently the standard therapy used and the one with better results. 5 However, this therapy encompasses several problems: (i) it is extremely expensive; (ii) patients with liver transplantation must continue lifelong immunosuppression; (iii) both carriers of TTR mutations who do not show clinical symptoms and patients in advanced stage of FAP cannot undergo liver transplantation; and (iv) limited organ availability. 6 The majority of the proposed strategies for FAP are based on the same therapeutic principles investigated for other amyloidosis, such as inhibiting aggregation and/or disrupting TTR amyloid by selective molecules. 7 Genetic and biochemical studies gave insights on prospective therapies encompassing inhibition of TTR aggregation by stabilization of mutant TTR. 8 Recently, the clinical efficacy of two chemical TTR stabilizers, tafamidis and diflunisal, respectively, has been shown in slowing the rate of progression of the disease. 9, 10 However, new strategies for therapy are still warranted.
The self-assembly properties of TTR T119M, a nonamyloidogenic variant commonly found in Portugal, have been intensely investigated because of milder disease in compound V30M/T119M heterozygote individuals. 11 Comparative studies of TTR variants V30M and T119M by semi-denaturing isoelectric focusing (IEF) revealed that the presence of the nonamyloidogenic variant increases the resistance of tetramers to dissociate into monomers, thus stabilizing TTR and exerting its anti-amyloidogenic effects by counteracting the weaker subunit interactions of V30M tetramers. 12, 13 More recently, Hammarström et al. 14, 15 showed that incorporation of one subunit of TTR T119M into a predominantly V30M TTR tetramer strongly stabilized the mixed tetramer against dissociation. These studies suggest that a gene therapy approach to express TTR T119M in liver is likely to have an impact on TTR fibril formation.
In recent years, adeno-associated virus (AAV) vectors have emerged as the most promising vectors for in vivo gene delivery. The lack of pathogenicity, the persistent gene expression and its ability to efficiently transduce dividing and non-dividing cells have increased the potential of AAV vectors as a delivery vehicle for in vivo gene therapy applications. 16 In an effort to increase the efficiency of AAV-mediated in vivo gene delivery, new capsids have been generated; AAV8 vectors have proven to be exceptionally efficient in liver transduction after intravenous delivery 17 and induce immune tolerance to the expressed transgene. 18 Here we assessed the effectiveness of liver-directed AAVmediated gene delivery of TTR T119M to reverse and/or prevent pathology in a TTR V30M transgenic mouse model.
RESULTS

TTR T119M expression in transgenic animals carrying the V30M TTR mutation
In this study, we aimed to establish a new approach for the treatment of FAP using liver-directed AAV gene transfer of TTR T119M in transgenic mice carrying the human TTR V30M variant in a TTR null background (hTTR V30M animals), hypothesizing that it would affect TTR deposition, particularly in the gastrointestinal (GI) tract. Therefore, we used systemic delivery of an AAV8 vector encoding TTR T119M under the control of a strong liver-specific promoter (Figure 1a) . hTTR V30M animals received a single injection in the tail vein of 3 × 10 11 vg of scAAV8-TTR T119M (n = 9), as well as of scAAV8-empty vector for the control group (n = 10); animals were euthanized 3 months later without any adverse events being observed in either group of injected animals.
Expression of TTR T119M was assessed in transgenic mice, both at protein and mRNA levels. First, we evaluated the presence of the two TTR variants in the plasma of injected animals and their identity by immunoprecipitation of the protein followed by mass spectrometry (MS) analysis. The m/z peaks corresponding to TTR tryptic peptides are highlighted in Figure 1b , according to the expected masses predicted by the in silico tryptic digestion of TTR, for the amino-acid substitutions. Peptides with mass 1398 Da, corresponding to sequence 42-54 (GSPAINVAMHVFR) of TTR V30M, were found in gel bands from all of animals (left panels), whereas peptides with mass 2390 Da corresponding to sequence 125-146 (YTIAALLSPYSYSTMAVVTNPK) of the mutated T119M form of TTR (right panels) were only found in bands from the serum of animals injected with scAAV8-TTR T119M.
In AAV8-T119M-injected animals, TTR plasma concentration was 55 ± 2.1 mg dl -1 , compared with 39 ± 2.1 mg dl -1 in control animals ( Figure 1c ), a significant increase (P = 0.0033) expected, as animals were infused with a vector that provides the cells with additional copies of a TTR expression cassette. Similarly, liver TTR mRNA was 58% higher in scAAV8-TTR T119M-injected animals than controls (Figures 1d, P = 0.0392). To confirm if this increase in total TTR mRNA was due to AAV-mediated TTR T119M expression, quantitative PCR-high-resolution melting analysis (HRM) was used to quantify the relative levels of TTR V30M and T119M transcripts; HRM is a simple solution for genotyping and mutation scanning based on the analysis of the melting profile of a PCR product, as sequence differences result in the formation of heteroduplexes changing the shape of the melting curve. 19, 20 We used primers specific for each one of the mutations and calculated the height of the melting curves generated, using serial dilutions of plasmids encoding TTR V30M or TTR T119M as standards curves, based on the method described for the quantification of DNA methylation. 21 Later, we sequenced the PCR fragments produced by this approach and confirmed the presence of each mutation amplified by the two different pairs of primers. This analysis showed TTR T119M mRNA to be~50% of transgenic TTR V30M mRNA (Figure 1e ). TTR T119M acts as a stabilizer in the plasma of transgenic animals carrying TTR V30M Previously, Alves et al. 22 have described normal thyroid hormone concentration in plasma, but increased T 4 binding to TTR in carriers of TTR T119M. Later, it was shown that TTR T119M has increased affinity for T 4 binding both in vitro and in vivo. 23 Using a plasma [
125 I]-T 4 binding assay, increased binding of T 4 to TTR in T119M-injected animals compared with control animals ( Figure 2a ). As no major differences were observed in the binding of thyroxine-binding globulin or albumin, the two other major T 4 binding proteins in plasma, we hypothesize that increased T 4 binding could be related to a higher TTR concentration in these samples, leading us to next investigate TTR stability in scAAV8-TTR T119M-injected transgenic mice.
Previous studies have described the stabilization effect of TTR T119M in plasma of FAP patients, preventing tetramer dissociation and thus contributing to a more benign form of the disease. 12, 14 The stabilization effect of TTR T119M in our study was investigated by IEF in a semi-denaturing polyacrylamide gel in the presence of 4 M urea. Plasma samples from animals injected with scAAV8-TTR T119M or transgene-empty vector were compared for band patterns and tetramer/monomer ratios. Under the conditions used, TTR presents a characteristic pattern of two main bands, representing monomers (normal and oxidized form), and several bands of lower isoelectric point (pl), representing different forms of tetramers. 12, 24 When analyzed in this system, plasma from the empty vector-injected animals show more intense bands at the monomer position and less at the tetramer position; in contrast, TTR T119M-injected animals present a higher amount of tetramer in relation to monomer. The tetramer/monomer ratio is significantly higher (P = 0.0079) in transgenic mice expressing TTR T119M as compared with empty vector transgenic animals (Figure 2b ), indicating that in these animals TTR has higher stability and higher resistance to tetramer dissociation.
Search for modified TTR species in tissues: an approach using proteomics The peripheral nervous system is the key target tissue for development of therapies for FAP. Although TTR deposition in dorsal root ganglia (DRG) is not apparent in hTTR V30M transgenic mice, different signaling pathways seem to be altered in DRG nonetheless. 25 Therefore, we evaluated pathways that may be changed by de novo liver expression of TTR T119M variant using a proteomics approach based on two-dimensional differential gel electrophoresis (2D-DIGE) analyses.
The DRG proteome was compared in animals injected with scAAV8-TTR T119M (n = 4) or empty vector (n = 4); a few protein spots showed a statistically significant (P o0.05) change in abundance between groups ( Figure 3 , Table 1 ). These spots were picked from the gels and identified by matrix-assisted laserdesorption ionization (MALDI)-time-of-flight (TOF)/TOF MS. TTR from injected mice was separated by PAGE and the isolated protein was analyzed by IEF. The different molecular species visualized in the IEF gel after Coomassie blue staining are indicated. Plasma samples from TTR KO mice injected with scAAV8-TTR T119M were used as controls for TTR stability, as only tetramers are detected. Plot corresponds to the densitometry quantification of the ratio tetramer/monomer. Error bars represent s.e.m. **P o0.01. For all panels, n = 9 for scAAV8-TTR T119M and n = 10 for empty vector-injected animals. All the gel images shown are representative for other gels run in parallel.
Five protein spots were identified as TTR species; based on molecular weight and pI, it was suggested that spots 788, 1633 and 1663 corresponded to tetrameric TTR, as spot 1679 corresponded to monomeric TTR. It was also noticed that the characteristic peptide for V30M mutation was only detected in the tetrameric protein form identified in spot 788, although the characteristic peptides for T119M were found in all protein spots identified as TTR. Interestingly, the increased quantity of tetrameric TTR in DRG of animals injected with TTR T119M and decreased monomeric TTR is in accordance to the higher ratio tetramer/monomer that we found in the serum of these animals.
Spot 607 was identified as a high molecular form of TTR, suggesting a possible modified form of TTR. To further identify it, several post-translational modifications were searched, including carbonylations, glycosylations, oxidations, methylations, among several other of the most common protein post-translational modifications. None of these post-translational modifications was identified with all certainty in the spots identified as TTR.
Induced expression of TTR T119M decreases TTR deposition in the GI tract of TTR V30M transgenic animals Extracellular TTR deposition in TTR V30M transgenic animals can be detected both in fibrillar and non-fibrillar forms depending on age and stage of disease. 26, 27 We analyzed the GI tract for the total amount of TTR deposition, both fibrillar and non-fibrillar, by immunohistochemistry (IHC), to assess the effect of scAAV8-TTR T119M on TTR deposition. Using a specific antibody against hTTR, we found lower TTR deposition in stomach (P = 0.0009) and colon (P = 0.0046) of T119M-injected mice compared with empty vectorinjected animals in the younger group of animals ( Figure 4a ).
We also assessed the therapeutic effect of T119M TTR overexpression in FAP progression in an additional group of animals, injected at 12 months of age (n = 10 for scAAV8-TTR T119M and n = 7 for empty vector). These animals were at a different stage of deposit progression, with TTR deposition already present at the beginning of the experiment. 26 However, animals treated at this age showed no differences in TTR deposition in stomach or colon (Figure 4b ).
Expression of TTR T119M decreases FAP disease biomarkers in TTR V30M transgenic animals Next, we analyzed the levels of the endoplasmic reticulum chaperone BiP (Grp78) and the extracellular matrix protein MMP-9 as these molecules have been shown to be upregulated in FAP, [28] [29] [30] [31] and thus can be used as disease biomarkers. Representative overlaid images of a 2D-DIGE gel of DRG protein extracts from animals injected with empty vector (n = 4) or scAAV8-TTR T119M (n = 4) and labeled with Cy3 and Cy5, respectively; indicated spots showed a statistically significant variation of spot volume with 95% confidence level (P o0.05); minimum MASCOT score 70. Fold change represents the change in abundance in scAAV8-TTR T119M over control animals injected with empty vector.
A gene therapy approach to FAPUsing semiquantitative IHC, we evaluated BiP levels in the GI tract organs where TTR deposition occurs; expression of TTR T119M led to a significant decrease in BiP levels both in stomach (P = 0.0332) and colon (P = 0.0075; Figure 5a ). To further confirm these results, we performed western blot analysis of these organs; BiP was significantly decreased only in colon (Figure 5b , P = 0.0354). This fact may be caused by the dilution factor introduced in the western blot analysis by organ homogenization; however, this difference observed by western blot analysis only in colon correlates with it being the same organ where we found higher differences by IHC.
Levels of MMP-9 were also assessed by semiquantitative IHC. As MMP-9 is upregulated only when fibrillar deposition is present, 28, 31 we would not expect to observe differences in both groups of animals, as these animals did not present Congo red-positive amyloid deposits (data not shown), as amyloid deposition in this animal model only starts by 11 months of age. 26 However, we found a significant difference in MMP-9 levels in colon (Figure 5c , P = 0.0333). The observation that colon is the organ where the major differences in disease biomarkers were found suggests that it could be the most affected organ in disease progression in this V30M mouse model.
DISCUSSION
With the present work, we proposed to establish the basis for what could in the future become a new treatment for FAP. Gene therapy approaches have arisen as new gene transfer, replacement and/or correction technologies have emerged and perfected over the last several decades. Nakamura et al. 32 reported the conversion of mutated TTR V30M to TTR WT in the liver of a Figure 4 . TTR deposition assessment in the GI tract of AAV-treated transgenic mice. (a) Representative IHC for hTTR in stomach and colon of the young animals experimental group. Scale bars, 100 μm. Plots correspond to the semiquantification of TTR staining represented as the ratio of the occupied area in the whole tissue. Error bars represent s.e.m. **P o0.01; ***P o0.001. n = 9 for scAAV8-TTR T119M and n = 10 for empty vector-injected animals. (b) Representative IHC for hTTR in stomach and colon of the old animals experimental group. Scale bars, 100 μm. Plots correspond to the semiquantification of TTR staining represented as the ratio of the occupied area in the whole tissue. Error bars represent s.e. m. n = 10 for scAAV8-TTR T119M and n = 7 for empty vector-injected animals.
transgenic mouse using single-stranded oligonucleotides. More recently, reduction of a specific mutated TTR gene expression was achieved using antisense nucleotides both in liver 33 and in the choroid plexus albeit to lower extent. 34 Currently, clinical trials to evaluate safety and tolerability of an antisense drug (phase 2/3 trial; www.isispharm.com; clinicaltrials.gov identifier NCT01737398) are ongoing, aiming to reduce the amount of mutant and normal TTR made by the liver. Other trials, involving small interfering RNA (phase 2 trial; www.alnylam.com; clinicaltrials.gov identifiers NCT01148953 and NCT01617967) were recently completed and first results show a specific and sustained reduction of TTR expression. 35 Here we investigated a different gene therapy approach based on the knowledge that compound heterozygotes V30M/T119M show more benign clinical manifestations of FAP, because of increased protein stability. 8, 11 Previous studies have shown that lentiviral vectors encoding TTR T119M can transduce hepatocytes and lead to the formation of more stable heterotetramers with amyloidogenic variants. 36 AAV vectors have emerged as the most powerful platform for in vivo gene delivery to liver mainly due to highly efficient transduction after systemic delivery and ability to mediate longterm transgene expression with no apparent toxicity. 37, 38 To enhance liver transduction after systemic administration, we used a self-complementary vector (for faster gene expression because of bypassing of second-strand DNA synthesis required upon infection by single-stranded AAV vectors to become transcriptionally active), encoding a strong liver-specific promoter and pseudotyped with highly liver-tropic AAV8 capsid. scAAV8 vectors have demonstrated higher transduction efficiency of murine livers, and are currently being tested in clinical trials for factor IX deficiency. [39] [40] [41] However, AAV8 vectors have also shown a wide tissue tropism after systemic infusion; 17, 42 in our experimental groups we did not detect quantifiable AAV vector derived TTR mRNA in any organs tested other than liver, including stomach, colon and DRG (data not shown), excluding the possibility that tissue TTR aggregates were related to local TTR synthesis rather than the physiological mechanism of its secretion by the liver.
We analyzed mRNA levels of each variant in liver by HRM. Despite being able to quantify TTR T119M mRNA as approximately 50% of TTR V30M mRNA, Hammarström et al. 14, 15 have shown that as little as one T119M monomer in the heterotetramer is enough to increase resistance to dissociation and thus prevent formation of aggregates. 4 We did not assess the ratio of V30M:T119M in heterotetramers that hypothetically are being formed in liver, however, TTR tetramers in plasma after gene transfer of TTR T119M were more stable than TTR V30M-only tetramers, as assessed by IEF (Figure 2b) . Furthermore, we have also shown an increase in tetrameric TTR, with concomitant decrease in TTR monomers, in DRG of T119M-injected animals, in accordance to our findings in plasma samples. Our 2D-DIGE approach also revealed a decrease of a high molecular form of TTR in T119M-injected animals ( Figure 3, Table 1 ), which may be compatible with reduction of TTR aggregates.
We observed this stabilization effect on the tetramer resulting from AAV-mediated expression of TTR T119M in liver and, most strikingly, we perceived reduced TTR deposition in the GI tract of hTTR V30M transgenic mice when the treatment was initiated at a young age. However, this gene therapy approach had no effect when treatment was administered to older animals. Our results indicate that the presence of a protective TTR variant does not impact pre-existing TTR aggregates, but it can exert a stabilization effect in TTR heterotetramers preventing dissociation and aggregate formation. 12, 14, 15 Together with decrease in TTR deposition, reduced levels of disease biomarkers such as BiP, an endoplasmic reticulum stress chaperone, were found in scAAV8-TTR T119M-injected mice. We also analyzed MMP-9, an extracellular matrix protein described to be upregulated in the presence of amyloid fibrils but not oligomeric TTR. 28, 31 Interestingly, differences were observed in colon, although amyloid deposits were not documented. However, Cardoso et al. 31 verified that in cell culture oligomeric TTR upregulates MMP-9 expression; therefore, we can hypothesize differences in MMP-9 expression to be dependent on disease stage.
In summary, we show that AAV-mediated expression of a protective TTR variant in liver stabilizes TTR V30M and decreases non-fibrillar deposition and disease biomarkers in the GI tract of a transgenic mouse model; patients expressing both TTR variants present a more clinically benign form of the disease likely related to decreased TTR deposition, an impact of the trans-supressor variant, as suggested by the present work. Taken together, our work paves the way in the study of treatments for FAP, as it opens new approaches that may be used to modulate/alter disease progression.
MATERIALS AND METHODS
AAV vector design and preparation
The AAV vector used in this study was modified from pAAV-CBA-mBgal-W 43 by removing the mBgal complementary DNA (cDNA) and replacing the CBA promoter with a liver-specific enhancer-promoter combination composed of the human apolipoprotein hepatic control region and human alpha-1-antitrypsin gene promoter followed by the hAAT 5'untranslated region and a modified SV40 intron, as previously described. 44 This enhancer-promoter was synthesized by PCR amplification and matches the sequence published by Nathwani et al. 44 The vector was further modified into a self-complementary design by deletion of the terminal resolution site (as described by McCarty et al. 39 ) in the AAV2 inverted terminal repeat near the AHA promoter to generate plasmid scAAV-AHA-W. TTR T119M cDNA was cloned into this plasmid by PCR amplification followed by sequencing. Vector stocks made with AAV8 capsid were produced by transient transfection of 293T cells and purification by iodixanol gradient centrifugation followed by anion-exchange chromatography using HiTrapQ columns (GE Healthcare, Uppsala, Sweden), as described, 45 or cesium chloride gradient centrifugation. Transgene-empty vector was also produced as described.
Titers of vector stocks were determined by real-time quantitative PCR using primers and probe specific for the bovine growth hormone polyadenylation signal present in these vectors, and represented as viral genomes (vg) ml -1 .
Animal procedures
Mice were handled according to National rules and to the European Community Council Directive (86/609/EC) for the care and handling of laboratory animals. All animals were maintained at 22 ± 2°C, humidity 45-65%, under a 12-h light-dark cycle and fed regular chow and tap water ad libitum. Three-month-old transgenic animals carrying human TTR V30M in a TTR null background 26 (hereafter referred to as hTTR V30M animals) were injected in the tail vein with 3 × 10 11 vg of scAAV8-TTR T119M (n = 9) or with the same amount of empty vector (n = 10). A second experiment was conducted using the same transgenic model at the age of 12 months (n = 10 for scAAV8-TTR T119M and n = 7 for empty vector) with the same conditions. Three months after injection, the animals were euthanized following deep anesthesia with a mixture of ketamine/medetomidine; all tissues, including stomach, colon, liver and DRG, were immediately excised and transected; a portion was frozen at − 70°C, whereas the other was fixed in 4% neutral buffered formalin and embedded for paraffin processing. Blood was collected from the inferior vena cava in EDTAcoated syringes and plasma was separated by centrifugation.
TTR mass spectrometry TTR variants identification by MALDI MS analysis was performed after immunoprecipitation with anti-human TTR antibody (1:20, Dako, Glostrup, Denmark). Briefly, 25 μl of serum was incubated with anti-human TTR antibody and kept overnight at 4°C with stirring. Next, protein A Sepharose beads were added and allowed to mix for 1 h at room temperature with agitation. The beads were washed and the complex eluted with sodium dodecyl sulfate-loading buffer. Finally, samples were fractioned on a 15% acrylamide sodium dodecyl sulfate-polyacrylamide gel electrophoresis (PAGE) gel under denaturing conditions and the gel was stained following the Coomassie colloidal blue protocol. The TTR bands were excised from the gel and in-gel digestions were performed, after reduction and alkylation, by adding modified porcine trypsin (Promega, Madison, WI, USA). Peptide mass spectra were acquired using an Applied Biosystems 4800 Plus MALDI-TOF/TOF MS equipment (Framingham, MA, USA) . The resulting peptide masses lists were compared with the theoretical tryptic peptide masses lists generated for each mutant TTR sequence (P02766).
Plasma TTR quantification
Plasma TTR was quantified by enzyme-linked immunosorbent assay as previously described. 46 Briefly, 96-well plates (Maxisorp, Nunc, Roskilde, Denmark) were coated overnight at 4°C with a polyclonal rabbit antihuman TTR antibody in carbonate/bicarbonate coating buffer, and blocked with 5% (w/v) skim milk in phosphate-buffered saline; diluted plasma was applied to the wells for 1 h at room temperature; a second anti-human TTR antibody peroxidase-conjugated was then used. Development was performed with 5 mM 2,2′-azinobis (3-ethybenzthiazoline-6-sulfonic acid, ABTS, Sigma, St Louis, MO, USA) and optical density was measured at 405 nm. TTR concentration was calculated from a standard curve ranging from 5 to 340 ng ml -1 .
Quantitative real-time PCR
For gene expression quantification, total RNA from mice liver was isolated using PureLink RNA Mini Kit (Ambion, Grand Island, NY, USA) following the manufacturer's instructions. cDNA synthesis was performed using random hexamers with Superscript II following manufacturer's instructions (Invitrogen, Grand Island, NY, USA). cDNA was then quantified in an iQ5 Bio-Rad real-time PCR machine with iQ Sybr Green Supermix (Bio-Rad, Hercules, CA, USA). Ribosomal gene 18S was used for normalization. The ΔΔC T method was used for quantification calculations. 
High-resolution melting analysis
The relative quantity of the two TTR variants present in mice liver was measured by HRM using the synthesized cDNA. To generate standard curves, linearity tests were performed by HRM using two primer sets for TTR V30M and TTR T119M, respectively. Serial dilutions of plasmids encoding either V30M or T119M TTR cDNA were used as standards to create reconstituted samples with a constant V30M DNA quantity (100 ng) but decreasing the percentage of TTR T119M plasmid DNA from 100 to 0% (10% interval). Each dilution was then amplified with the two primer sets and submitted to HRM. HRM was carried out on a CFX96 Touch Real-Time PCR Detection System (Bio-Rad). PCR was performed in 15 μl volume containing 1x SsoFast EvaGreen Supermix, 200 nM of each primer and 2 μl of cDNA template. The amplification protocol was 3 min at 95°C followed by 40 cycles of 10 s at 95°C and 10 s at 60°C. HRM was performed at 95°C for 1 min, 55°C for 3 min and with a ramping from 65 to 95°C rising by 0.2°C for 10 s. Melting curves were normalized using the Precision Melt Analysis software (Bio-Rad) before and after the major fluorescence decrease. A differential profile was then evaluated for each sample by comparing fluorescence at the melting point against the value of fluorescence of the negative control (TTR V30M DNA). All experiments were performed in triplicate.
As reproducibility is an important issue in any quantitative determination, we tested the intra-and inter-assay variability of HRM using two primers sets (V30M and T119M) in 10 liver samples carrying variable T119M transductions. To evaluate intra-assay reproducibility, five replicates of the same V30M/T119M cDNAs were measured in a single HRM experiment. In addition, using the same samples and primers, we repeated the measurement in five consecutive experiments to determine inter-assay variability.
All PCR products were sequenced to confirm the presence of the point mutation.
Primer sequences: ; Perkin Elmer, Waltham, MA, USA) followed by separation of the plasma T 4 binding proteins by PAGE in a glycine/acetate buffer system, as previously described. 48 The gel was dried under vacuum and T 4 binding proteins were visualized by phosphor imaging (Thyphoon 8600, Molecular Dynamics, part of Amersham Pharmacia Biotech, Sunnyvale, CA, USA).
TTR tetrameric stability assays by IEF under semi-denaturing conditions
To perform this assay, 30 μl of plasma were separated in native PAGE and the gel band corresponding to TTR was excised and applied to an IEF gel. IEF was carried out in a polyacrylamide gel containing 5% ampholytes (pH range 4-6.5) and in the presence of 4 M urea, at 1200 V for 6 h, essentially as previously described. 8, 24 These semi-denaturing conditions allow the visualization of bands corresponding to TTR monomers, an oxidized form of monomer and tetramers. Proteins were fixed in 20% (m/v) trichloroacetic acid and stained with Coomassie blue. The dried gel was scanned with Molecular Imager GS800 calibrated densitometer (Bio-Rad); semiquantification of images was performed using the ImageJ software (NIH, Bethesda, MD, USA) and is presented as the ratio between tetramers and monomers compared with control. TTR null animals injected with same dose of scAAV2/8-TTR T119M were used as controls.
Two-dimensional differential gel electrophoresis
Differential protein expression between animals injected with empty vector or scAAV8-TTR T119M was determined in DRG (n = 4 for each group) disrupted at 4°C with a Potter-Elvehjem homogenizer. Proteins were extracted in lysis buffer containing 20 mM 3-(N-morpholino)propanesulfonic acid, 2 mM ethyleneglycol tetraacetic acid, 5 mM EDTA, 1%(v/v) Triton x-100 and a protease inhibitor cocktail (Sigma-Aldrich, St Louis, MO, USA). After centrifugation, the supernatant was precipitated with 2D Clean-up kit (GE Healthcare), according to the manufacturer's protocol. Dried pellets were dissolved in IEF DIGE buffer (GE Healthcare) for 2D gel electrophoresis. A last centrifugation was performed to remove any insoluble material. Protein concentration was determined with 2D Quant Kit (GE Healthcare) following the manufacturer's instructions. The samples and the internal standard (a pool of all samples for both treatment conditions) were labeled with CyDye DIGE Fluor minimal dyes (GE Healthcare) in accordance with the regular protocol. Samples and internal standard were loaded on a previously rehydrated IPG strip (Immobiline Dry Strips, 24 cm, pH 4-7, GE Healthcare). IEF was carried out on an IPGphor III system (GE Healthcare). After IEF, the proteins were reduced and alkylated by soaking the strip in rehydration buffer containing dithiothreitol and iodoacetamide. Separation of the second dimension was performed on 1.0 mm thick gels under low fluorescence glass plates (GE Healthcare). IPG strips were loaded on 12.5% acrylamide sodium dodecyl sulfate-PAGE gels. For the second dimension an Ettan DALTsix electrophoresis unit (GE Healthcare) was used.
The DIGE images were obtained with a laser-based scanner FLA-5100 (FujiFilm Life Science, Düsseldorf, Germany) under Image Reader FLA 5000 version 1.0 (FujiFilm Life Science). The gel images were then analyzed using Progenesis SameSpots analysis software version 3.3.1 (NonLinear Dynamics, Durham, NC, USA). Each spot with an analysis of variance P-value 40.05 or with an absolute abundance variation of o1.3-fold was excluded from further consideration. The P-value was calculated by the one-way analysis of variance test performed using the normalized spot volume of matching spots from the two conditions under study; this calculation compares the mean difference between conditions with its variance among biological replicates of the same condition. Similarly, principal component analysis was also carried out and any spots with a power value below 0.7 were also excluded.
Excised gel spots and bands were washed to remove stain traces and submitted to tryptic in-gel digestion. The obtained supernatants were recovered, peptides were desalted and concentrated using homemade micro-columns (GELoader tip, Eppendorf, Hamburg, Germany) with POROS R2 resin (Applied Biosystems). The tryptic peptides were eluted with a matrix solution (5 mg ml -1 α-cyano-4-hydrocynnamic acid in 50% (v/v) acetonitrile with 2.5% (v/v) formic acid) directly onto a MALDI target. Peptide mass spectra were acquired by Applied Biosystems 4800 Plus MALDI TOF-TOF Analyzer equipment. Data were acquired in positive MS reflector mode. Processing and interpretation of the MS spectra was performed with 4000 Series Explorer Software (Applied Biosystems). The resulting peak lists and fragmentation patterns were used to search for matches in an in-house compiled database of UniprotKB/Swiss-Prot database release 2013_03 (539616 sequence entries) using MASCOT search engine (version 2.2; Matrix Science, Boston, MA, USA). The processing parameters were set as follows: minimum mass accuracy of 30 p.p.m. for the parent ions, an error of 0.3 Da for the fragments, one missed cleavage in peptide masses, and cysteine carbamidomethylation and methionine oxidation as fixed and variable amino-acid modifications, respectively. Peptides were only considered if the ion score indicated extensive homology (Po 0.05).
Immunohistochemistry
Three-μm-thick sections were deparaffinated in Histoclear (National Diagnostics, Atlanta, GA, USA) and hydrated in a descendent alcohol series. Endogenous peroxidase activity was quenched with 3% hydrogen peroxide in phosphate-buffered saline for 30 min. Tissue slides were incubated with blocking buffer containing 4% fetal bovine serum and 1% bovine serum albumin in phosphate-buffered saline for 1 h at room temperature and then incubated overnight at 4°C with primary antibodies diluted in blocking buffer. Primary antibodies used were: rabbit polyclonal anti-human TTR (1:300, Dako), goat polyclonal anti-BiP (Grp78, 1:50, Santa Cruz Biotechnology, Dallas, TX, USA) and rabbit polyclonal anti-MMP-9 (1:1500, Abcam, Cambridge, UK). Antigen visualization was performed using Vectastain Elite ABC Reagent (Vector Labs, Burlingame, CA, USA), according to the manufacturer's instructions, and diaminobenzidine (Sigma-Aldrich) was used as substrate for color development. Sections were counterstained with hematoxylin, dehydrated in an ascendant alcohol series and coverslipped under Entellan (Merck Millipore, Darmstadt, Germany). On parallel control sections, incubation with primary antibody was replaced by blocking buffer; staining was absent under these conditions.
Sections were examined with an Olympus BX50 light microscope equipped with an Olympus DP71 (Barcelona, Spain) digital camera for image acquisition by an observer blinded to samples identification. Five images were taken from each organ, covering different areas, to achieve its full representation. Semiquantitative immunohistochemistry analysis was performed using Image-Pro Plus software (Media Cybernetics, Rockville, MD, USA), by measuring the ratio between the area occupied by the pixels corresponding to the immunohistochemical substrate's color and the pixels of the total area, in every image taken. The ratios of all images were then averaged and pooled for each experimental group.
Western blot
Stomach and colon samples were homogenized in lysis buffer containing 20 mM 3-(N-morpholino)propanesulfonic acid, 2 mM ethyleneglycol tetraacetic acid, 5 mM EDTA, 30 mM NaF, 40 mM β-glycerophosphate, 20 mM sodium pyrophosphate, 1 mM sodium orthovanadate, 1 mM phenylmethylsulfonyl fluoride, 0.5% NP-40 (all from Sigma-Aldrich) and 1x protease inhibitors cocktail (GE Healthcare Bioscience, Pittsburgh, PA, USA). Total protein concentration in cell lysates was determined by the Bio-Rad assay kit (Bio-Rad) using serial dilutions of bovine serum albumin as protein standard; 50 μg of total protein were separated in a 12% polyacrylamide sodium dodecyl sulfate-PAGE gel and then transferred onto a 0.2 μm pore nitrocellulose membrane (Whatman, GE Healthcare, Pittsburgh, PA, USA) using a wet transfer system. Primary antibodies were rabbit polyclonal antiBiP (Grp78, 1:1000, Abcam) and mouse monoclonal anti-α-tubulin (1:10 000, Sigma-Aldrich) for normalization. The enhanced chemiluminescense method (GE Healthcare Bioscience) was used to develop the blots. Quantitive analysis of western blot images was performed using the ImageJ software (NIH).
Statistical analysis
Experimental results shown are presented as mean ± s.e.m. Statistical significance was evaluated by Student's t-test, unless otherwise stated. Differences were considered significant for P o0.05 (*), Po0.01 (**) or Po0.001 (***), as designated. Statistical analyses were performed using GraphPad Prism 5.0 for Mac OS X (La Jolla, CA, USA).
